Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study

Acta Diabetologica

Volumn 51, Issue 6, 2014, Pages 1015-1023

  Kim, Seoyoung C ^a,c   Glynn, Robert J ^a   Liu, Jun ^a   Everett, Brendan M ^a   Goldfine, Allison B ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b JOSLIN DIABETES CENTER   (United States)

^c NONE   (United States)

Author keywords

Cardiovascular disease; Dipeptidyl peptidase 4 inhibitor; Heart failure; Type 2 diabetes

Indexed keywords

GLITAZONE DERIVATIVE; LINAGLIPTIN; MEGLITINIDE; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RISK ASSESSMENT; AGED; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; RISK FACTOR;

AGED; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CAUSE OF DEATH; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84919461875     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0663-2     Document Type: Article

References (29)

1. Amori RE, Lau J, Pittas AG (2007) Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298(2):194–206
2. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A (2012) Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 344:e1369
3. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE (2006) Sitagliptin Study 021 Group: effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29(12):2632–2637
4. Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, Dugi KA, Woerle HJ (2012) 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 380(9840):475–483
5. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q (2008) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 31(12):2315–2317
6. Faillie JL, Azoulay L, Patenaude V, Hillaire-Buys D, Suissa S (2014) Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ 348:g2780
7. Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, Rios LP, Malaga G, Wong E, Sohani Z et al (2014) Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 348:g2366
8. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR (1999) Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100(10):1134–1146
9. Wit MA, de Mulder M, Jansen EK, Umans VA (2013) Diabetes mellitus and its impact on long-term outcomes after coronary artery bypass graft surgery. Acta Diabetol 50(2):123–128
10. Tarquini R, Lazzeri C, Pala L, Rotella CM, Gensini GF (2011) The diabetic cardiomyopathy. Acta Diabetol 48(3):173–181
11. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369(14):1317–1326
12. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S et al (2013) Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med 369(14):1327–1335
13. White WB (2013) Results from examine. In: 49th European Association for the Study of Diabetes September 26 2013, Barcelona, Spain
14. American Diabetes Association (2014) Standards of medical care in diabetes–2014. Diabetes Care 37(Suppl 1):S14–80
15. Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA (2007) Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298(22):2634–2643
16. Andrade SE, Harrold LR, Tjia J, Cutrona SL, Saczynski JS, Dodd KS, Goldberg RJ, Gurwitz JH (2012) A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf 21(Suppl 1):100–128
17. Saczynski JS, Andrade SE, Harrold LR, Tjia J, Cutrona SL, Dodd KS, Goldberg RJ, Gurwitz JH (2012) A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf 21(Suppl 1):129–140
18. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH (2004) Accuracy of medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 148(1):99–104
19. Choma NN, Griffin MR, Huang RL, Mitchel EF Jr, Kaltenbach LA, Gideon P, Stratton SM, Roumie CL (2009) An algorithm to identify incident myocardial infarction using Medicaid data. Pharmacoepidemiol Drug Saf 18(11):1064–1071
20. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S (2011) A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol 64(7):749–759
21. Rubin D (1997) Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127(8 Pt 2):757–763
22. Austin PC (2007) The performance of different propensity score methods for estimating marginal odds ratios. Stat Med 26(16):3078–3094
23. Austin PC (2009) Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom J Biom Z 51(1):171–184
24. Kleinbaum D, Klein M (2012) Evaluating the proportional hazards assumption. In: Gail M, Krickberg K, Samet J, Tsiatis A, Wong W (eds) Survival analysis: A self-learning text, 3rd edn. Springer, Berlin
25. White WB, Pratley R, Fleck P, Munsaka M, Hisada M, Wilson C, Menon V (2013) Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab 15(7):668–673
26. McMurray J (2013) The Vildagliptin in Ventricular Dysfunction Diabetes trial (VIVIDD). In: European Society of Cardiology Heart Failure Association: May 26 2013, Lisbon, Portugal: 99
27. Ussher JR, Drucker DJ (2012) Cardiovascular biology of the incretin system. Endocr Rev 33(2):187–215
28. Johnson ES, Bartman BA, Briesacher BA, Fleming NS, Gerhard T, Kornegay CJ, Nourjah P, Sauer B, Schumock GT, Sedrakyan A et al (2013) The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf 22(1):1–6
29. Ray WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158(9):915–920